Governments urged to fight pneumococcal disease
Teva Pharmaceutical Industries Ltd. has announced that its subsidiary, Teva Pharmaceuticals USA, Inc., has signed an agreement with AstraZeneca to settle patent litigation involving Teva’s U.S. generic version of AstraZeneca’s Pulmicort (Budesonide) Respules including all claims for patent infringement and damages. Teva launched its generic budesonide respules in the U.S. on November 18, 2008. The
Full Post: Teva announces agreement on generic Pulmicort Respules patent challenge
Pneumococcal disease, one of the world’s leading causes of death and serious illness, must be recognised as an urgent global health issue together with HIV, malaria and TB, say the UK All-Party Parliamentary Group (APPG) on Pneumococcal Disease Prevention in the Developing World in a report launching at the House of Lords today. Between 700,000 and one million children under the age of five die each year from pneumococcal disease, equivalent to malaria and more than AIDS and tuberculosis.
These child deaths are a largely preventable tragedy. A vaccine against pneumococcal disease exists and is being used in the UK. The impact of this vaccine has been seen in England and Wales where there has been a 59% reduction of cases of invasive pneumococcal disease among children under the age of two since it was introduced in September 2006. But developing countries, who account for more than 90% of pneumococcal deaths, do not have access to these vaccines. The UK Parliamentarians urge donor and developing countries to continue their commitment to fighting this killer disease through vaccination, strengthening healthcare systems, sustained political will, funding for research and international coordination of efforts.
“We have a responsibility to help reduce the global health problem of pneumococcal disease, which is under-recognised and until recently, has had few dedicated efforts made to tackle it,” said Chair of the Group Dr. Des Turner, MP. “The APPG developed this report in response to the urgent need to improve child survival and tackle the devastating impact of pneumococcal disease in the developing world. As we’ve highlighted, governments and international organisations have a crucial role to play in preventing pneumococcal disease in the developing world, and need to maintain and grow commitments to mobilise the resources needed to fight the disease.”
Additionally, the report covers the disease burden, financing and also the future of the fight against pneumococcal disease.
“We commend APPG’s recommendation to elevate pneumococcal disease alongside other global killers including AIDS, malaria and TB,” said Dr Orin Levine, Executive Director, GAVI’s PneumoADIP. “Vaccination is a proven, safe and effective solution to the global burden of this deadly disease. It is vital that the donor community maintain and increase their commitment, ensuring these vaccines are made available to those who need them most.”
To ensure the introduction of lifesaving vaccines to developing countries, the first pilot Advance Market Commitment (AMC), a novel financing mechanism, is investing in accelerating the introduction of this vaccine to where it is needed most, the developing world. The AMC for pneumococcal disease is expected to make an important contribution to saving the lives of over 7 million children by 2030.
GAVI Executive Secretary Julian Lob-Levyt said, “New financing mechanisms such as an AMC have the potential to save millions of lives. To reach Millennium Development Goal 4, which calls for a two-thirds reduction in childhood mortality by 2015, we must urgently use solutions like the AMC to provide dramatic and rapid impact. Ensuring faster access for children to a vaccine against pneumococcal is a fundamental step towards this goal.”
Prof Tumani Corrah, Unit Director & Chairman, Executive Management Board, MRC in The Gambia, said, “Countries in Africa and across the developing world see the impact of pneumococcal disease on our families on a daily basis. The All Party Parliamentary Group on Pneumococcal Disease Prevention in the Developing World is doing an invaluable job in raising the profile of this forgotten but devastating disease. As their report states, it is essential that governments across the world remain committed to fighting this deadly bacteria.”
Evidence for the report was gathered from across the globe from individuals, governments, multi-laterals, NGOs, funding organisations and the pharmaceutical industry.
Commonly used pneumococcal polysaccharide vaccines do not appear to be effective for preventing pneumonia, found a study by a team of researchers from Switzerland and the United Kingdom. In many industrialized countries, polysaccharide pneumococcal vaccines (PPVs) are currently recommended to help prevent pneumococcal disease in people aged 65 and over and for younger people with
Full Post: Pneumococcal polysaccharide vaccines do not appear to protect against pneumonia
The University of Maryland, Baltimore (UMB) has licensed a pediatric vaccine against Shigella bacteria to PATH, an international nonprofit group, to support clinical trials, with the goal of developing a vaccine suitable for children in resource-poor countries. Each year, an estimated 1.1 million people die from Shigella infections, a major cause of diarrhea and dysentery,
Full Post: Live oral Shigella vaccine licensed to PATH
Malaria kills more than one million people every year so the news that an effective vaccine could be available within five years is more than welcome. Malaria is caused by Plasmodium falciparum, the most deadly malaria parasite transmitted by the female anopheles mosquito and is the leading killer of children under the age of five
Full Post: Vaccine against malaria could be ready in 5 years
Mayo Clinic research shows adults with asthma are at increased risk of serious pneumococcal disease caused by Streptococcus pneumoniae, the most common bacteria causing middle ear infections and community acquired pneumonia. It also causes blood stream infections and brain infections. According to the Centers for Disease Control, pneumococcal infection is one of the leading causes
Full Post: Adults with asthma at increased risk of serious pneumococcal disease
Measles deaths worldwide fell by 74% between 2000 and 2007, from an estimated 750,000 to 197,000. In addition, the Eastern Mediterranean region*, which includes countries such as Afghanistan, Pakistan, Somalia, and Sudan, has cut measles deaths by a remarkable 90% during the same period. By reducing measles deaths from 96,000 to 10,000, the region has
Full Post: Measles on the decline globally